Vigonvita Life Sciences completed its global offering and H-share listing on the Hong Kong Stock Exchange, raising gross proceeds of $76 million—before the exercise of the over-allotment option—for a market capitalization of $720 million. The Hong Kong public offering was oversubscribed by 6,237 times.
Vigonvita Life Sciences is a biopharmaceutical company that develops small-molecule drugs for neuropsychiatry, reproductive health and viral infection.
S&C acted as Hong Kong and U.S. counsel to the sole sponsor, CITIC Securities (Hong Kong), and the underwriters, including CLSA, China International Capital Corporation Hong Kong Securities, ABCI Securities Company, China Galaxy International Securities (Hong Kong), CCB International Capital , China Everbright Securities (HK), Futu Securities International (Hong Kong), Tiger Brokers (HK) Global and Zhongtai International Securities.
The S&C team was led by Gwen Wong, Kay Ian Ng and Ching-Yang Lin, and included Gehuan Liu, Stella Yang, Steve Lee and trainee solicitor Olivia Zhao.